Treatment of invasive candidiasis in the era of Candida resistance
Authors:
- 28 July 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 29 (5) , 457-462
Abstract
Purpose of review: The increasing incidence of drug-resistant Candida brings a new challenge to the treatment of invasive candidiasis. Although cross-resistance among azoles and echinocandins was generally uncommon, reports of multidrug-resistant (MDR) Candida markedly increased in the last decade. The purpose of this review is to understand mechanisms and risk factors for resistance and how to tackle antifungal resistance. Recent findings: The paper describes the action of the three main classes of antifungals - azoles, echinocandins and polyenes – and Candida's mechanisms of resistance. The current evolution from cross-resistance to multiresistance among Candida explains the modern glossary − multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) – imported from bacteria. MDR Candida most commonly involves acquired resistance in species with intrinsic resistance, therefore it mostly involves C. glabrata, C. parapsilosis, C. krusei, C guilliermondii or C. auris, which is intrinsically multidrug resistant. Finally, strategies to tackle antifungal resistance became clearer, ideally implemented through antifungal stewardship. Summary: Avoiding antifungal's overuse and selecting the best drug, dose and duration, when they are needed, is fundamental. Knowledge of risk factors for resistance, microbiological diagnosis to the species, use of susceptibility test supported by antifungal stewardship programs help attaining effective therapy and sustaining the effectiveness of the current antifungal armamentarium.Keywords
This publication has 46 references indexed in Scilit:
- Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistanceNature Communications, 2016
- Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014Open Forum Infectious Diseases, 2015
- Echinocandin Resistance in CandidaClinical Infectious Diseases, 2015
- Mechanisms of echinocandin antifungal drug resistanceAnnals of the New York Academy of Sciences, 2015
- Antifungal drug resistance among Candida species: mechanisms and clinical impactMycoses, 2015
- Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory ConcentrationsClinical Infectious Diseases, 2013
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012
- Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicansAntimicrobial Agents and Chemotherapy, 2011
- Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 PatientsAntimicrobial Agents and Chemotherapy, 2011
- Risk Factors for Fluconazole-Resistant CandidemiaAntimicrobial Agents and Chemotherapy, 2010